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directly on sputum specimens or on clinical isolates, and the results 
are available within 2 days. 
In conclusion the MGIT method is rapid and simple to perform 
and can be used for all antituberculous drugs. It requires no expen- 
sive equipment which makes it appropriate for s m a l l  laboratories in 
developing countries where the incidence of TB is high. 
The INNO-LIPA R f  TB test is another rapid and reliable tool 
for the diagnosis of TB and rifampicine resistance. It can be used im- 
medntely on sputum specimens transported in alcohol to a reference 
laboratory when PCR can not be performed locally. 
Tailon'ng the Choice of Different Blood Culture 
Media to Meet the Needs of Clinicians 
G. Fadda. Ist. di Minobiologia, Universitd Cattolica del Sam Cuore, 
Rome, M y  
Actual generation of blood culture systems offers the opportunity 
of rapid results to clinicians and a range of media that can be used 
to tailor dngnostic protocols related to dinical needs. The isolation 
of spechc pathogens f b m  blood cultures may be associated with 
very specific situations. The dSerent blood culture media contain 
reagents and growth factors to improve the selective detection of 
microorganisms, thus enabling the use of proper sets of media to 
match c h c a l  expectations. 
It has been widely demonstrated that the presence of antibiotic 
removal devices, such as resins, in the broth increases the recovery of 
bacteria fiom blood cultures of patients under drug therapy and is 
also helpful in monitoring the effectiveness of treatment, especially 
for those bacteria with a high risk of emergent resistance. Pediatric 
patients represent a very particular population: our experience shows 
that the use of a specific medium for children does not reduce the 
sensitivity of the system and allows to inoculate low amounts of 
blood (0.1 to 3.0 ml) and to recover some si&icant pediatric bac- 
teria such as, for example, Streptocorn agaiactiae. Specific mema have 
also been formulated to support and reveal growth of mycobacteria 
and fungi h m  blood. We are currently using these media, which 
ensure the detection of these organism for their selective proper- 
ties. In our experience, the adopted formulae of the fungal and 
mycobacterial media enhance the growth of these organism with a 
considerable reduction in the average time-to-detection. 
Conclusions: Often the clinical findmgs are not specific to indi- 
cate a selection of media, but epidemiological monitoring of isolates 
for each deparhnent can help in conmlling the efficiency of proto- 
cols. In our experience, the clinical impact of tailoring the choice of 
a e r e n t  blood culture media is positive and should result in better 
patient care and lower costs. 
miniaturized method providng identification of fIequently isolated 
aerobic catalase-positive and -negative Gram positive bacteria indud- 
ing staphylococci, streptococci, coryneforme bacteria, lactobad 
and bacilli within 4 hours. The advantage of the Crystal in com- 
parison to existing commercial micro-identification systems is the 
use of a slngle panel for the whole range of cknically relevant Gram 
positive bacteria. Another advantage is reduced hands-on time for 
panel inoculation, more rapid result readmg since no addition of 
reagents is required, and the overall ease of use of the system. 
Together with rapid susceptibility testing the same-day bacterial 
identification will have a major impact on the care and outcome of 
hosp ihed  patients with infection. Additionally, t h ~ ~  will improve 
cost-effectiveness in medical microbiology laboratories. 
Is63( Clinical Value of Rapid Results in Micmbiology - 
The American Experience 
P. Murray. Warhington University School dMedicine, Saint Louis, MO, 
USA 
bdical changes in the US health care system has had profound 
effects on laboratory medicine. An emphasis of out-patient dngnos- 
tic work, decreased length of hospitalization, and rapid turn-around 
times for tests has refined the workfiow and selection of testing pro- 
cedures for c h c a l  microbiology laboratories. Modifications of test 
selection have been seen in methods for microbial detection, micro- 
bial identification, and antimicrobial susceptibility testing. Improved 
microbial detection methods include the use of molecular probes 
(e.g., for mycobacteria, viruses), immunoassays (e.g., C. dtjiale, Gi- 
ardia, Entamoeba), direct biochemical assays (e.g., H. pylon urease 
test), and automated instruments (e.g., blood culture, mycobacte- 
rial culture). Improvements in microbial identification include use 
of probes (e.g., for many bacteria, fungi, viruses) and biochemical 
tests measuring preformed enzymes (e.g., Stnphylococcus, Smptococ- 
rus, iVeissm'a/Haemophiius, enteric gram-negative bacilli, anaerobes). 
Rapid antimicrobd susceptibility testing is acheved using 4-7 hour 
same day systems with novel indcators of bacterial p w t h .  The im- 
pact of these changes on laboratory and c h c a l  practices will be 
discussed. 
Susceptibility testing of yeasts 
Antifungal Susceptibilii Testing: New NCCLS 
interpretive Guidelines 
J. Rex. University of EXAS Medical School, Houston, Taus, USA 
Is62) Clinical Value of BBL Crystal Gram Positive 
Testing 
H.K. Geiss, H. von Baum, H.-G. Sonntag. Institute ofHygiene, 
University ofHeidelbeq, I h F  324, 69120 Heide!bq, Germany 
Cost containment in medical microbiology laboratories is becom- 
ing increasingly important. In contrast to clinical chemistry, rapid 
methods and automation in microbiology is far h m  being generally 
accepted. 
Regarding rapid methods, speed is just one of the three factors 
whch should direct the provision of microbiology services. Addi- 
tionally, results obtained by rapid methods in diagnostic laboratories 
must be accurate, clinically relevant, and generated and transmit- 
ted to the chician quickly enough to be meaningfd for the better 
management of the patient. 
The BBL Crystal Fbpid Gram Positive ID System is an advanced 
A reproducible broth-based method for antifungal susceptibility test- 
ing (M27) has been developed by the NCCLS in collaboration with 
many laboratories. Standardizing factors such as inoculum, incuba- 
tion time and temperature, medium, test format, and endpoint de- 
termination, has reduced inter-laboratory variability in MIC results 
h m  up to 50,000-fold (seen in early work) to 2-fold, thus providing 
a cornerstone for comparative studies. The method will shortly be 
released as M27-A ("A" for approved). 
Once a reproducible method is available, developing and d- 
dating interpretive breakpoints is the next task. For fluconazole, 
large datasets correlating M27 MIC with outcome are adable  
for OPC (mostly in AIDS patients) and candidemia (mostly in 
non-neutropenic patients). For itraconazole, such datasets are a d -  
able only for OPC. Based on analyses of these datasets, breakpoints 
have been proposed vs. isolates of Condida (Table). The familiar (S) 
and (R) categories are used, but the new S-DD category (Suscep- 
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tibility is Dose (or Delivery) Dependent), requires explanation. The 
use of fluconazole in doses of 100-800 mg/d (1-12 mg/kg/d) leads 
to great variations in blood level. Animal studies and clinical data 
have shown that increased doses can be used to treat infections due 
to isolates with higher MICs. Thus, isolates with MICs in the S-DD 
range are thought susceptible if maxunal doses (2400 mg/d or z 6  
mg/kg/d) are used. Isolates with MICs in the S range appear sus- 
ceptible to lower doses. With itraconazole, isolates with MICs in 
the S-DD range appear responsive if drug absorption problem are 
addressed and levels of z0.5 pg/mL are achieved. 
These guidelines are a major step towards clinical use of andfun- 
gal susceptibility testing, but substantial work remains. Buildmg on 
the principles established by M27, simplhed methods using other 
techniques have recently been described. In addition, projects are 
underway to study problem either not address or not resolved by 
M27, such as measuring susceptibility of Candida to amphotericin B, 
susceptibdity of C. neoformans, and testing of moulds. 
Table. Interpreuve Guidelines for Susceptibib testina in uilm of Candida specin 
~~ ~ 
Antlfungal Surcepuble Suscepublc-dose Intermcdute Resxtanr 
Agent (S) dependent (S-DD) (I) (R) 
Fluconazole 5 8  1632 ?64 
ltriconizole 50.125 0.254.5 21 
Flucytoune 54  8-1 6 232 
Based on data from large clinical trials, breakpoints for Candida 
species against the indicated agents were derived and are shown in 
pg/mL. C. kmsei is assumed intrinsically resistant to fluconazole and 
need not be tested. Due to the problems with flucytosine monother- 
apy, flucytosine breakpoints are based on integration of pharmacoki- 
netic and population microbiological data rather than clinical trials 
data. Interpretive guidelines for other drugs and’other fungi are 
problematic and have not yet been developed. 
Antifungal Resistance Mechanisms 
D. Sanglard. Znstitut de Microbiologie, Centre Hospitalin Uniuersitaire 
kudois,  I01 1 Lausanne, Switzerland 
Resistance of yeasts to andfungal agents has been observed mostly 
in AIDS patients with orophgyngeal candidiasis treated with azole 
anhfungal agents, and especially fluconazole. DSerent types of resis- 
tance can be distinguished acquired or intrinsic resistance to a spe- 
cific azole andfingal agent (fluconazole) or acquired cross-resistance 
to merent azole derivatives (fluconazole, itraconazole or ketocona- 
zole). Whde C. albicans isolates generally acquire resistance to azole 
derivatives, C. glabrafa isolates are generally intrinsically less suscep- 
tible to fluconazole only In t h i s  laboratory, it has been shown that 
resistance can develop in C. albicons by i) the over expression of 
different multidrug efflux transporter genes, each with &tinct or 
overlapping substrate specificity or by ii) afEnity alteration to azole 
andfungal agents through specific mutations of their target (a cy- 
tochmme P450). In resistant C. glabrata isolates so far investigated, 
acquired cross-resistance to azole annfungal agents is caused mainly 
by the over expression of a distinct multidrug efflux transporter gene, 
while intrinsic resistance to fluconazole seems to be due to the con- 
stitutive expression of another transporter gene. A major impact of 
the involvement of multidrug efflux transporters in the resistance 
to azole andfungal agents is that these transporters could mediate 
cross-resistance to a number of structurally unrelated compounds, 
among which could be alternative or even new antifungal agents. 
(s661 Recent Advances in Yeast Susceptibility Testing 
C.P.A. van Boven. Leiden University Hospital, Leiden, The Netherlands 
Fungal susceptibility testing methodology has lagged behind bac- 
terial susceptibility testing by about 30 years. U n d  recendy, only 
a few reference laboratories performed susceptibility testing with 
yeasts, and fewer s t i l l  tested molds. There are now several relatively 
standardized and reproducible quantitative methods for fluconazole 
susceptibility testing of yeast, these include the proposed standard 
US-NCCLS broth tube and microdilution methods, and the 2 agar 
gradient methods, disk a s i o n  and E-test. These methods are very 
similar to current bacterial test methods, are relatively easy to per- 
form and interpret, are amenable to automated reading, and enable 
hospital chical laboratories to begin testing appropriate Candida 
isolates. 
Several recent studies have compared and evaluated these meth- 
ods. Recent publications of the US-NCCLS breakpoint recomrnen- 
dations for fluconazole and itraconazole provide essential guidelines 
for interpreting test results. 
Results of testing fluconazole will be briefly reviewed in this pre- 
sentation. Susceptibility tests for molds sbll require significant devel- 
opment efforts before they can be performed routinely in hospital 
laboratories. 
Multicountry Candidemia Survey 
€? Sandven. National Znstitute ofPublic Health, Oslo, Noway 
Objectives: The objectives of this study were to survey contem- 
porary fungal blood culture practices in various countries and to 
obtain data on yeast species isolated from blood culture in the same 
countries. 
Methods: Each participant w a s  asked to complete a question- 
naire giving a basic demographic description of each medical center, 
the blood culture systems and procedures used, and to report fungal 
blood culture isolates. Up to now information from 8 countries and 
30 laboratories has been obtained Argentina (3), Brazil (2) Colom- 
bia (l), Malaysia (l), Norway (8), Philippines (4), Spain (5) and 
Venezuela (6 laboratories). 
Results: For 27 of the laboratories data from 1992 to 1994 were 
reported. The study period for the merent laboratories varied &om 
3 to 24 months (mean 18 months). A manual blood culture method 
was used by most of the laboratories in South America, while 12 of 
the European laboratories used automatic systems. Sixteen labora- 
tories used both aerobic and anaerobic bottles, while 5 laboratories 
used anaerobic (unvented) bottles only Two laboratories used the 
isolator system. The incubation period for fungal blood cultures var- 
ied h m  3 to 40 days (median 7 days). The total number of isolates 
reported was 534, whlch included 238 (45%) Candida albicans, 61 
(11.5%) C. parapsilosis, 22 (4%) C .  fropicalis, 19 (3.5%) C. glabrata, 
and 5 (1%) C. knrsei. A high proportion of yeast isolates (25%) were 
not identified to species level (Argentina 21%, Brazil 6%, Colom- 
bia 47%, Malaysia lo%, Norway 7.5%. Phikppines 37%, Spain 5.5% 
and Venezuela 46%). C. albicatrc isolates were probably identifed 
in all countries (using the germ tube test). The occurrence of t h i s  
species measured as percentage of the total isolates showed a wide 
geographic variation: Argentina 53%, Brazil 12.5%, Colombia 16%, 
Malaysia 0%. Norway 65%, Philippines 63%. Spain 44%, Venezuela 
45%. Ctyprococcus neofomans constituted 47% of the isolates &om 
B d  and 15% f b m  Argentina. 
Conclusions: This study has shown that the dmribution of yeast 
species recovered h m  blood culture varies quite remarkably be- 
tween countries. It is therefore important that systemic yeast isolates 
are identified to species level and that the distribution of fungal 
species in each country is registered. 
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A Global Survey Yeast Susceptibility to 
Fluconazole 
J.M. Torres-Rodriguez ’ , G. Quind6s ’. ’ Cmp de Recerca en 
Micologia Expm’mental I Clhica, lMLM. /Universifat Autbnoma de 
Barcelona, Spain, ’ e t .  Minobiology Far. Medicine, Euskadi University, 
Bilbaq Spain 
Fluconazole is currently the azole antifungal drug most used for the 
treatment of yeast mfections because of its high rate of efficacy, low 
toxicity and simplicity of a b t r a t i o n .  As a result of the wide use 
of fluconazole, particularly as prophylaxis and treatment of oropha- 
ryngeal candidosis in HN-infected patients, changes in the suscepti- 
blity of some strains of Candida albirans and the emergence of other 
species less susceptible in vitro such as Candid0 ktusk and Tomlopsis 
(Candida) glabratu have occurred. The significance of these effects on 
the course of the disease is controversial. 
Stukes of susceptibility to Flucon&ole have been pubhhed by 
many laboratories in several countries, most of them h m  the USA. 
In general terms the results seem to be similar but there are Wer- 
ences in methodology and procedure. 
In a multicentre survey of in vitro antifungal resistance in yeasts of 
medical importance isolated form Spanish patients, the susceptibility 
to fluconazole was 90.2%; only 4% of C. albiram strains were not 
susceptible. Most resistance was seen in C. glabrata and C. guillier- 
mondii. AU C. tropicalis were susceptible to fluconazole. Conclusions 
of thts study were that resistance to antifungals is very low in Spain 
and it is related to a few non-albicanc species. 
Glauser et al conducted a multicentre study in 23 Werent coun- 
tries with 2231 consecutively isolated Candida strains in whch a 
fluconazole difFusion assay was performed. The results of this study 
showed the 97.1% of C. albicans strains were susceptible to this an- 
tifungal. When other species of Candida were studied the suscepti- 
bility was lower (83.4%). The results of the difLsion test correlated 
with MICs (NCCLS proposals) for susceptible or intermediate saains 
when the zones of inhibition were 18-25 mm. 
These results suggested a low in vitro world-wide resistance of 
Candida albirnns to fluconazole and variable susceptibility depending 
on the other Candida species considered. 
Recent advances in HIV pathogenesis 
Is69) immunologic and Virologic Factors During 
Primary Infections: Modulation of the Clinical 
Course and Therapeutic Implications 
G. Pantaleo. CH 
No abstract available. 
T cell dynamics in HIV-1 infections studied by 
telomere length and CD4+ T cell repopulation 
kinetics following anti-viral therapy 
F. Miedema’, K.C. Wolthers‘, N.G. Pakker ’, D.W. Notermans’, 
S.A. Danner’, P.T.A. Schellekens ’. ’Central Lob. Neth. Red Cross 
Blood Transf: Service, €3 Universify $Amsterdam, Amsterdam, 7he 
Netherlands, ’In& Dis., Trop. Med. and A I D S  t3 N A T E C ,  Academic 
Medical Centre, Amsterdam, The Netherlands 
In a group of 14 HIV-infected persons, mean loss of telomere length 
in PBMC over 3 to 9 years was sigmficantly increased compared 
to mean loss of TRF length in 7 healthy contmls. Loss of telom- 
ere length in HIV infection was found exdusively in CD8+ T cells 
and not in CD4+ T cells. Loss of telomere length could not be 
explained by differential telomerase activity. This provides evidence 
that turnover in the course of HIV-1 infection can be increased con- 
siderably in CD8+ T cells, but not in CD4+ T cells. T ~ I S  implies 
that CD4+ T cell decline in HIV-1 infection might be caused by 
&bition of CD4+ T cell renewal. To further study T cell renewal 
capacity and kinetics we evaluated the repopulation of CD4+ and 
CD8+ T cell subsets and their functional improvement during the 
first 36 weeks of treatment with ritonavir, 3TC and zidovudine that 
induced a strong and persistent reduction of the plasma and lym- 
phoid viral load. A strikingly distinct kinetics for CD4+ CD45RO+ 
and RA+ cells was observed. CD45RO+ cell repopulation followed 
a biphasic pattern, with a steep increase in the first 5 weeks and a 
gradual slow increase the following months. In contrast, the naive 
CD62L+ cells over the follow up period showed a slow and gradual 
increase with a mean increase of 10’ cells per day. In addition, a sus- 
tained improvement of T cell function was seen in the patients. Our 
results demonstrate that immunereconstitution following anti-viral 
therapy may be slow and may not readily reach normal levels of 
immunocompetence. 
The Impact of potent antiretroviral treatment on 
viral burden and immune depletion in lymphatic 
tissues 
A.T. Haase. Department dMicrobioloa, University ofMinnerota, 
Minneapolis, M N ,  U S A  
Quantitative image analysis of sections of lymphatic tissues (LT) after 
in situ hybridization to reveal viral RNA, or immunohistochemisay 
to identlfy subsets of CD4+ T cells af50rd.s new opportunities to 
understand the pathogenesis of infection and response to treatment. 
I wiU describe the results of recent experiments on the response to 
combinations of antiretroviral therapy in LT that define the kinet- 
ics and magnitude of this response. I wiU also describe the rate of 
CD4+ T cell replacement that suggests a “Red Queen” mechanism 
of immune depletion in HIV-1 infection. 
Rationale for Immuno-Based Therapeutic 
Intervention in Combination with Antiviral 
Agents 
H.C. Lane. USA 
No abstract available. 
Antibiotic resistance in otitis media: Clinical 
problem or hypothetical risk? 
otitis Media: Pathogenesis and Medical Sequelae 
M.J. Tulow. UK 
No abstract available. 
Is74( Choosing the Antibiotic - Pharmacodynamics 
W.A. Craig. USA 
No abstract available. 
